Loading
BeOne Medicines Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 17 Jun 2026.
BeOne Medicines Ltd.: what insiders have been doing
This page follows insider dealings at BeOne Medicines Ltd. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 317 filings came from 36 insiders.
Open-market activity splits into 11 purchases and 184 sales totalling €330.6M; 10 insiders sit on the buying side and 17 insiders on the selling side. The totals do not cover 42 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 10 senior executives. Oyler John filed the largest sale, €14.0M, on 12 August 2026, which represents 0.039% of the company's market value.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 317 filings, this issuer sits above that mark. Since 2016, the database holds 17 purchases and 300 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 5.34 bn USD and net income of 286.9 m USD.
The latest purchase dates back some time: it was published 123 days ago, on 17 June 2026. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Other companies in the same sector with recent insider buying flagged by our signals: Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
577
Thresholds
n/a
Buy Volume
€42M
17 ops. · all time
Sell Volume
€4B
300 ops. · all time
Who traded when
BuySaleOyler John99 sales
Wang Xiaodong1 buy26 sales
Oyler John Victor1 buy17 sales
Chan Henry Lee13 sales
Wu Xiaobin8 sales
Wang Lai6 sales
+17 other insiders
Since the insiders bought
- +36.7%Entry US$270.15 · Close 16 Oct 2026 US$369.19
- +40.5%Entry US$262.68 · Close 16 Oct 2026 US$369.19
- +40.5%Entry US$262.68 · Close 16 Oct 2026 US$369.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate BeOne Medicines Ltd. Strong Buy (bullish), based on 28 analysts. Average price target: US$432.80.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,976 of 24,158 companies
56.0
score / 100
Value43
Quality69
FCF yld2.1%
Earn yld0.7%
EV/EBITDA·
ROE15%
Gross mgn87%
Net mgn5.4%
Debt/EBITDA1.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$367.00
Analyst consensus
28 analystsStrong buy
US$370.00Target US$432.80(+18%)US$528.00
Income statement
RevenueUS$5.3B
Gross profitUS$4.7B87% margin
EBITDAUS$616.8M12% margin
Net incomeUS$286.9M10.7% margin
Valuation
PER (trailing)64.5x
PER (forward)35.6x
P/Book8.0x
Beta0.52
Balance sheet & cash
Market capUS$41.5B
Total debtUS$1.1B
Free Cash FlowUS$861.1M
Debt / Equity40%
Profitability & ownership
ROE14.7%
ROA7.5%
% insiders17.3%
% institutions33.2%
Last declaration on 16 October 2026
Declarations577 total
403,351 shares@ HK$26.9990.0034% mcap3.2% of flowShareXHKGHKEX:DA20261016E00366
403,351 sharesShareXHKGHKEX:DA20261016E00365
31,027 shares@ US$36.900.0028% mcap2.8% of flowAmerican Depositary SharesSEC:0001662982-26-000006:0
7,167 shares@ US$349.56130.0061% mcap6.1% of flowAmerican Depositary SharesSEC:0001662982-26-000006:1
10,361 shares@ US$350.47410.0088% mcap8.8% of flowAmerican Depositary SharesSEC:0001662982-26-000006:2
5,681 shares@ US$351.39580.0048% mcap4.8% of flowAmerican Depositary SharesSEC:0001662982-26-000006:3
6,558 shares@ US$352.56910.0056% mcap5.6% of flowAmerican Depositary SharesSEC:0001662982-26-000006:4
1,260 shares@ US$353.23670.0011% mcap1.1% of flowAmerican Depositary SharesSEC:0001662982-26-000006:5
403,364 sharesShareXHKGHKEX:DA20260930E00534
403,364 shares@ HK$28.06040.0034% mcap4.8% of flowShareXHKGHKEX:DA20260930E00535
1,115 shares@ US$375.000.0010% mcap7.6% of flowAmerican Depositary SharesSEC:0001980648-26-000027:0
160 shares@ US$356.96620.0001% mcap0.2% of flowAmerican Depositary SharesSEC:0001662982-26-000004:1
120 shares@ US$358.70670.0001% mcap0.2% of flowAmerican Depositary SharesSEC:0001662982-26-000004:2
40 shares@ US$359.160.0000% mcap0.1% of flowAmerican Depositary SharesSEC:0001662982-26-000004:3
2,241 shares@ US$361.05290.0019% mcap2.8% of flowAmerican Depositary SharesSEC:0001662982-26-000004:4
4,239 shares@ US$362.16750.0037% mcap5.4% of flowAmerican Depositary SharesSEC:0001662982-26-000004:5
3,499 shares@ US$363.09950.0030% mcap4.5% of flowAmerican Depositary SharesSEC:0001662982-26-000004:6
3,419 shares@ US$364.06750.0030% mcap4.4% of flowAmerican Depositary SharesSEC:0001662982-26-000004:7
2,047 shares@ US$365.84790.0018% mcap2.6% of flowAmerican Depositary SharesSEC:0001662982-26-000004:8
14,525 shares@ US$366.57830.013% mcap18.7% of flowAmerican Depositary SharesSEC:0001662982-26-000004:9
738 shares@ US$367.22520.0007% mcap1.0% of flowAmerican Depositary SharesSEC:0001662982-26-000004:10
31,028 shares@ US$36.900.0027% mcap4.0% of flowAmerican Depositary SharesSEC:0001662982-26-000004:0
1,181 shares@ US$345.3830.0010% mcap2.5% of flowAmerican Depositary SharesSEC:0001662982-26-000002:0
2,841 shares@ US$346.15750.0024% mcap6.0% of flowAmerican Depositary SharesSEC:0001662982-26-000002:1
25 of 577 declarations
About BeOne Medicines Ltd.
BeOne Medicines Ltd. is a global biopharmaceutical company listed on the NASDAQ (United States) under the ticker ONC, with additional listings in Hong Kong and Shanghai. The company, formerly known as BeiGene, completed a name change and redomiciliation on May 27, 2025, moving its place of incorporation from the Cayman Islands to Switzerland while keeping its Nasdaq Global Select Market listing intact. For international investors, this means BeOne is a U.S.-listed oncology company with a Swiss legal domicile and a globally distributed operating footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1651308/000110465925053039/tm2515777d11_posasr.htm))
Founded in 2010 by John V. Oyler and Xiaodong Wang, BeOne was built around a clear mission: to develop innovative cancer therapies and make them more accessible across global markets. The company’s operational footprint spans major hubs including San Carlos, California; Cambridge, Massachusetts; and Basel, Switzerland, alongside manufacturing and R&D capabilities in the United States, China, Europe, and Latin America. BeOne also highlights a broad global research network, with clinical development and commercial activities across multiple continents. ([beonemedicines.com](https://beonemedicines.com/about/history/?utm_source=openai))
Read moreShow less
BeOne is primarily an oncology-focused business. Its commercial foundation rests on two key medicines: BRUKINSA (zanubrutinib), a BTK inhibitor used in several blood cancers, and TEVIMBRA (tislelizumab), an anti-PD-1 immunotherapy used in solid tumors and hematologic indications. Beyond these marketed products, the company is advancing a broad pipeline that spans blood cancers, lung cancer, breast/gynecological cancers, gastrointestinal cancers, and certain rare cancers. BeOne states that it has more than 30 investigational medicines in development, underscoring a pipeline-driven growth model rather than a narrow single-asset profile. ([beonemedicines.com](https://beonemedicines.com/science/medicines/?utm_source=openai))
From a competitive perspective, BeOne operates in a highly crowded oncology landscape against major global pharma groups and specialist biotech peers. Its differentiation lies in an integrated development model, a wide geographic commercialization strategy, and a stated focus on improving patient access. The company reports regulatory approvals for its internally developed medicines in more than 75 countries, which gives it meaningful international reach and supports the view that it is building a global oncology platform rather than a purely regional business. ([beonemedicines.com](https://beonemedicines.com/about/our-company/faqs/?utm_source=openai))
Recent developments have been constructive. In February 2026, BeOne reported full-year 2025 revenue of $5.3 billion and highlighted strong global momentum for BRUKINSA. In May 2026, the company announced U.S. FDA approval of BEQALZI (sonrotoclax), and it also received FDA Priority Review for TEVIMBRA in a HER2-positive first-line indication. These updates reinforce the company’s clinical execution and regulatory momentum, both of which are central to the investment case in oncology biotech. ([ir.beonemedicines.com](https://ir.beonemedicines.com/news/beone-medicines-announces-fourth-quarter-and-full-year-2025-financial-results-highlighting-global-success-of/6559b41c-7beb-45ca-bc76-5e1c9cdb26cc?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
